Affy's Answer to Next-Gen Sequencing: On-Chip 'Enzymatic Sequencing Reactions' | GenomeWeb
NEW YORK (GenomeWeb News) - Affymetrix said today that it is working on a new technology that combines DNA sequencing and microarrays.
 
Speaking at the JPMorgan Healthcare Conference in San Francisco today, Stephen Fodor, Affy's chairman and CEO, said the company will deploy enzymatic sequencing reactions directly on arrays that have captured portions of the genome, using new chemistry that "allows us to use both polymerase and ligase labeling reactions."
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The White House has created a list of cuts, including to the NIH, that could be in a budget bill for this year.

The US National Institutes of Health is to allow applicants to cite preprints just as they would any other research paper, ScienceInsider reports.

Two manuscript pages handwritten by Charles Darwin are going on the auction block, according to the Los Angeles Times.

In PNAS this week: tool to track transcriptome-wide binding, evidence of balancing selection on behavior-linked genes, and more.